You can share it to WeChat via the Qr code.
Enter the applet sharing event using WeChat scan.
As one of the key directions of biological industry, Antibody drugs continue to make new breakthroughs. With the continuous progress of technology, clinic and the turning point of commercialization, Bispecific /Multi-specific Antibody and ADCs has became industry focus as the frontier innovation field. However, we face concentrated targets layout, the homogenization of project approval, severe challenges of druggability & developability, process development & scale-up and CMC strategic & compliance.
· How to deeply explore Biological mechanisms/clinical needs?
· How to differentiate target selection and combination strategy?
· How to better design/engineer molecules to improve efficacy and reduce negative effects/toxicity?
· How to deal with complex structure's scale-up and early-phase CMC challenges?
· How to promote innovative drugs (XDC/Multi-specific Antibody…)?
Based on the above situation, BioCon China 2022, as the annual conference with the highest participation of Chinese biopharmaceutical enterprises, will launch a series of conferences that focus on Antibody in Shanghai Marriott Hotel Parkview on March 22-23. It will provide higher quality, deeper level, newest topics of global antibody drugs which focus on Bispecific/ Multi-specific Antibody and ADCs. This conference intends to build a professional and high-quality platform for domestic and foreign companies to discuss policies, technologies, display products and develop businesses. Fully promote the development of the biopharmaceutical-antibodies industry!
Antibody industry ( mAb/BsAbs/NanoAb/ADCs and Other Antibodies ) chain: R&D and Manufacturing Institutes and Companies, industrial parks and investment institutions, upstream and downstream service providers
BioCon China, which has successfully held for eight years, is aimed to build platform for Chinese biopharmaceutical companies, domestic and foreign regulatory agencies and leading international biopharmaceutical companies. With eight years of experience that focusing on biopharmaceutical industry, BioCon China has accumulated 10000+ participants from global senior biopharmaceutical industry, 500+ industry-leading service and product suppliers, and 700+ industry leaders have participated in expert lectures and seminars.
With the development of biopharmaceutical industry, the Antibody Forum focused on the whole process of antibody drugs: early discovery, preclinical research, process and CMC development, clinical medicine, commercial production and marketing, etc. This year, it has made efforts to focus on the Bispecific/Multi-specificantibody, ADCs and other conjugated drugs. BioCon-Antibody will continue to explore industry's hotspots, build a platform for the upstream and downstream within the industry, and innovate with colleagues.